GMED — Globus Medical Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $69.99
- YTD price return
- -19.84%
- YTD total return
- -19.84%
- Market cap
- 9.3B
- Enterprise value
- 8.9B
- Shares outstanding
- 132.5M
- 52W low
- $69.49
- 52W high
- $101.40
- From 52W high
- -30.98%
- From 52W low
- +0.72%
- 52W range
- 2%$69.49–$101
- Beta
- 0.96
Volume
- Rel volume
- 0.62×
- 30D volume
- 1.8M
- 30D $ vol
- 140.5M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- −$3.6M
- Insider net 3M
- −$5.8M
- Insider net 1Y
- −$13.3M
Form 4 transactions by trade date, as filed; latest on file 2026-11-10.
Fundamentals
- Sales (ttm)
- 3.1B
- Sales/share
- $23.70
- EPS (ttm)
- $4.07
- FCF (ttm)
- 766.5M
- FCF/share
- $5.79
- Book value/share
- $36.21
- Net margin
- 17.76%
- ROE
- 11.63%
- ROA
- 10.09%
- Current ratio
- 4.30
Growth (CAGR, ttm) · 10Y
- Sales
- +13.36%+36.79%+22.09%+18.92%
- Net income
- +31.61%+52.27%+24.42%+16.84%
- FCF
- +32.28%+81.07%+23.93%+19.92%
- Shares
- -1.02%+4.75%+5.48%+3.29%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- +32.39%+39.49%+17.59%+12.80%
- Sales/share
- +14.53%+30.58%+15.75%+15.13%
- FCF/share
- +33.65%+72.86%+17.50%+16.09%
- Book value/share
- +10.17%-0.12%+16.42%+15.66%
- Price
- -16.33%+15.37%-0.15%+12.82%
- Total return
- -16.33%+15.37%-0.15%+12.82%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 17.2×
- P/OI (ttm)
- 13.6×
- Fwd P/E
- 13.1×
- P/S (ttm)
- 3.0×
- P/B (mrq)
- 1.9×
- P/FCF (ttm)
- 12.1×
- EV/EBITDA (fy)
- 9.2×
- EV/Sales (ttm)
- 2.8×
- FCF yield (ttm)
- 8.27%
- Buyback yield (realized, 1y)
- 0.59%
- Shareholder yield (realized, 1y)
- 0.59%
- Buyback yield (cash, ttm)
- 3.49%
- Shareholder yield (cash, ttm)
- 3.49%
Vs own 10Y history
- P/E
- 0th
- P/OI
- 1st
- P/S
- 2nd
- P/B
- 10th
- P/FCF
- 0th
Bar = where today’s multiple sits in GMED’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-17#
Data provided bySource: Twelve DataFundamentals#
Operating income
5Y CAGR +33.9%10Y CAGR +10.8%YoY +29.3%EPS (diluted)
5Y CAGR +31.2%10Y CAGR +12.9%YoY +18.2%Free cash flow
5Y CAGR +34.2%10Y CAGR +23.2%YoY +5.1%TTM: operating cash flow $925.9M, capex −$159.4M
Q3 2026: operating cash flow $265.2M, capex −$40.4M
Shares (diluted)
5Y +35.7%10Y +42.7%YoY +0.5%Net income
5Y CAGR +39.4%10Y CAGR +16.9%YoY +18.7%About Globus Medical#
Data provided bySource: Twelve DataGlobus Medical Inc. Class A Common Stock represents ownership in Globus Medical, a medical device company focused on musculoskeletal care. The company develops and commercializes products for spine and orthopaedic applications, including implant systems, surgical instruments, and enabling technologies used in hospitals, physician practices, and surgical centers. Its portfolio supports procedures for spinal disorders, bone healing, and other complex musculoskeletal conditions, making it a significant supplier in the healthcare equipment market. Globus Medical also provides integrated solutions that combine devices, instrumentation, and technology to support surgical workflows and patient treatment. Headquartered in Audubon, Pennsylvania, Globus Medical serves healthcare providers in the United States and internationally.
Audubon, PA·6,000 employees·Medical Devices·globusmedical.com·As of Oct 28, 2026
Recent filings#
- Nov 10Insider sale · TOBIN JAMES R (Director) sold 71,666 Class A shares for $5.4M on 2 days since Sep 15
- Nov 5Earnings · Earnings release — EPS $1.23 vs $1.20 est. (+2.5%); revenue $763.7M (−1% y/y) 12.8%
- Aug 18Insider sale · ZARRILLI STEPHEN T (Director) sold 25,000 Class A shares for $2.2M at $87.04
- Aug 6Earnings · Earnings release — EPS $1.34 vs $1.12 est. (+19.6%); revenue $789.6M (+6% y/y) 1.6%
ETFs holding GMED#
18 of the 193 ETFs ChartRow carries live hold GMED. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| VBK | Vanguard Small-Cap Growth ETF | 0.3% |
| IJH | iShares Core S&P Mid-Cap ETF | 0.2% |
| MDY | SPDR S&P MidCap 400 ETF Trust | 0.2% |
| VHT | Vanguard Health Care ETF | 0.1% |
| VB | Vanguard Small-Cap ETF | 0.1% |
| VXF | Vanguard Extended Market ETF | 0.1% |
| IWS | iShares Russell Mid-Cap Value ETF | 0.1% |
| IWR | iShares Russell Midcap ETF | 0.1% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +12.61% | -1.13% |
| JNJ | Johnson & Johnson | +9.05% | -1.36% |
| ABBV | AbbVie Inc. | +2.59% | -0.59% |
| MRK | Merck & Co. Inc. | -1.77% | -0.75% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | -2.93% | -5.42% |
| NVS | Novartis AG | +5.65% | -0.67% |
| TMO | Thermo Fisher Scientific Inc. | -0.47% | -0.66% |
| AMGN | Amgen Inc. | +5.88% | -0.95% |
